Abstract
Background: Mucinous adenocarcinoma of the rectum is a molecularly distinct subtype of rectal cancer (RC), associated with a poor response to chemoradiotherapy. Immune checkpoint inhibitors are anti-cancer therapeutics that can overcome tumour mediated immune suppression in solid-organ tumours. Previous work from our group, found significant correlation between mucinous RC and elevated expression of various immune checkpoints. The aim of the current study was to validate our previous findings within our own clinical cohort, and further characterise the immune landscape of mucinous RC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
